Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    More Data is Needed to Prove the Safety of Metformin
    • Fang LIU, Nephrologist
    • Other Contributors:
      • Yanhuan FENG, Ping FU, Yujie LIAO

    Dear Editor, Metformin is the most widely used hypoglycemic agent in the world. But the application among the diabetic patients who have the chronic kidney disease(CKD) is still controversial. What gave us a pleasant surprise was the observational study written by Ekstrom et al found that there were no increased risks of acidosis/serious infection in patients with renal impairment according to the large numbers of patient...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Metformin is a safe medication in mild-to-moderate chronic kidney disease.
    • David Arroyo, Nephrologist
    • Other Contributors:
      • David Arroyo, Soledad Garcia de Vinuesa, and Jose Luno

    Dear Editor,

    Ekstrom and colleagues publish a very interesting observational study comparing the rates of various outcomes depending on the type of antidiabetic drug prescribed.(1) This large population-based study presents some limitations, such as baseline difference between groups, attributing outcomes to initial treatment regardless of changes over time, or grouping diverse outcomes such as acidosis and infec...

    Show More
    Conflict of Interest:
    None declared.